Samsung Biologics Eyes Another Industry First This Year—Aims for ‘5 Trillion Won Club’
Samsung Biologics posted record operating profit and revenue in 2025, targets 5 trillion won milestone as Plant 5 and U.S. expansion drive further growth.
Hanmi Pharmaceutical Co., Ltd. reported a 4.0% rise in Q2 operating profit to 60.4 billion won, beating market expectations on strong sales of Rosuzet and Amosartan, and growth in its high-margin CDMO business, despite a 4.5% drop in revenue.
#YonhapInfomax #HanmiPharmaceutical #OperatingProfit #Rosuzet #CDMOBusiness #Q2Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=73926
Hanmi Pharmaceutical Posts Q2 Operating Profit of 60.4 Billion Won on Growth of Rosuzet and Amosartan (Comprehensive)
Hanmi Pharmaceutical Co., Ltd. reported a 4.0% rise in Q2 operating profit to 60.4 billion won, beating market expectations on strong sales of Rosuzet and Amosartan, and growth in its high-margin CDMO business, despite a 4.5% drop in revenue.
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=64634
Samsung Bioepis Dismisses Concerns Over Potential Dual Listing
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
Yonhap Infomax News